Physician profile
Jamie Meyer
NPI 1043692932
$1,181.62
in general payments reported to CMS, 2019-2025
26 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $466 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.63 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $155.28 | 2023-2025 | Trodelvy |
| Genzyme Corporation | $108.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.65 | 2023-2025 | Tagrisso, Onglyza, Calquence |
| Daiichi Sankyo INC. | $79.27 | 2023-2025 | Enhertu, Datroway |
| Seagen INC. | $75.99 | 2025 | |
| Springworks Therapeutics, INC. | $69.62 | 2024-2025 | Ogsiveo |
| Pfizer INC. | $61.10 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $49.01 | 2025 | |
| Genentech USA, INC. | $46.41 | 2024 | Perjeta, Phesgo, Kadcyla |
| Taiho Oncology, INC. | $46.16 | 2024-2025 | |
| Eisai INC. | $42.90 | 2023-2025 | |
| Astellas Pharma US INC | $42.23 | 2024-2025 | Xospata, Padcev |
| Abbvie INC. | $40.44 | 2025 | |
| Celgene Corporation | $35.28 | 2023-2024 | Pomalyst, Reblozyl |
| Jazz Pharmaceuticals INC. | $33.14 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.92 | 2024 | Keytruda |
| Sun Pharmaceutical Industries INC. | $25.08 | 2025 | |
| Agios Pharmaceuticals, INC. | $22.08 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.70 | 2025 | Opdivo |
| Sobi, INC | $19.25 | 2025 | |
| Beigene USA, INC. | $18.95 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $18.17 | 2024 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $17.93 | 2024 | Alunbrig |
| Janssen Biotech, INC. | $16.43 | 2024 | Rybrevant |
| Emd Serono, INC. | $15.01 | 2024 | |
| Iovance Biotherapeutics, INC. | $7.67 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.